DISCUSSION
psoriasis
PSORIASIS
Results from IMMspire demonstrated clinically meaningful efficacy with risankizumab, regardless of dose (75 or 150 mg); all patients achieved the primary end points of clinical response at week 16. Most patients achieved skin clearance assessed by PASI 90 at week 16. In addition, most of the patients who received risankizumab achieved DLQI 0/1 (no effect on patient's life) at week 16, which may suggest that risankizumab may help improve patient's quality of life. Overall, long‐term treatment with risankizumab demonstrated durable high rates of skin clearance in patients with GPP or EP. All patients who continued with risankizumab therapy maintained a clinical response at week 160.Risankizumab was generally well tolerated by patients with GPP or EP, and no new safety signals were identified. The safety profile of risankizumab observed through 160 weeks of therapy and follow‐up through 180 weeks was consistent with the safety profile of risankizumab observed through 172 weeks of treatment in patients with psoriasis.IMMspire has some limitations. First, the interpretation of efficacy and safety outcomes is limited by the lack of a placebo group. Second, the open‐label nature of the study may introduce bias as patients and investigators were aware of the study treatment. Last, the small sample size of the study may overestimate the magnitude of efficacy and AEs. Despite these limitations, findings from the present study suggest that there are positive treatment benefits for Japanese patients with GPP and EP.In conclusion, the results from IMMspire showed clinically meaningful and durable efficacy of risankizumab over time in patients with GPP or EP. Efficacy was achieved at week 16 and maintained throughout treatment, and up to the last follow‐up visit. The safety profile was consistent with the safety profiles outlined in other psoriasis studies with risankizumab treatment. These results suggest that risankizumab may be an effective long‐term treatment option for GPP or EP.